Business Daily Media

Business Marketing


AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

  • Written by PR Newswire


  • Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer
  • FOLFIRINOX is the most widely used treatment for pancreatic cancer patients in the US, Canada and most European countries
  • This new data supports clinical studies investigating the combination of AMP945 in a second major treatment regimen in pancreatic cancer
  • Amplia has filed a patent to cover the use of FAK inhibitors in combination with FOLFIRINOX and related treatment regimes

MELBOURNE, Australia, May 29, 2023 /PRNewswire/ -- Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to announce new data showing the efficacy of its investigational FAK inhibitor, AMP945, in a preclinical model of pancreatic cancer, when used in combination with FOLFIRINOX treatment. FOLFIRINOX, a combination of four chemotherapies used in the treatment of pancreatic cancer patients, is currently a widely-used treatment in many major markets around the world including the US.

New data from preclinical studies conducted in the laboratory of Prof. Paul Timpson at the Garvan Institute of Medical Research in Sydney, demonstrate that mice treated with AMP945 in addition to FOLFIRINOX show improved overall survival compared to those treated with FOLFIRINOX alone. The data, available in the Meeting Abstracts for the forthcoming American Society of Clinical Oncology meeting in Chicago, USA, (here[1])[1] describe studies in mice bearing pancreatic cancer tumours derived from a human patient. AMP945 was given in the days preceding FOLFIRINOX treatment (given on a 12-day cycle) resulting in a statistically significant increase in survival (up to 35% approx.) compared to FOLFIRINOX-only treated mice.

Dr Chris Burns, Amplia's CEO and Managing Director commented: "The exciting results from this mouse study further indicate the potential of AMP945 in pancreatic cancer treatment when used in combination with standard-of-care therapies. In light of this data, we have filed a patent to cover the use of FAK inhibitors, and particularly AMP945, in combination with FOLFIRINOX and related treatment regimes."

With this data, and the Company's previously reported preclinical data demonstrating the benefit of combining AMP945 with gemcitabine and nab-paclitaxel, AMP945 has shown promising activity in models of pancreatic cancer with the two most common first-line chemotherapy regimens for treatment of the disease.

Prof. Nick Pavlakis, a medical oncologist at the Royal North Shore Hospital in Sydney, and an investigator in the current ACCENT trial, commented: "FOLFIRINOX is employed under certain conditions in Australia and more broadly in the USA and Europe, and the data from this study, coupled with the developing safety and tolerability data from Amplia's current ACCENT trial, provide strong support to undertake a future clinical study of AMP945 with FOLFIRINOX."

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

About AMP945

AMP945 is an orally bioavailable small molecule FAK inhibitor with a best-in-class profile. The compound is currently undergoing a Phase 1b/2a trial in pancreatic cancer patients in combination with gemcitabine and nab-paclitaxel (the ACCENT trial) in Australia. More information about the ACCENT trial, including a list of participating sites, can be found via our website and at under the identifier NCT05355298[2].


FOLFIRINOX is combination chemotherapy consisting of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin used in the treatment of pancreatic cancer. In Australia, FOLFIRINOX is reserved for younger, fitter patients whereas in other countries (e.g. US, UK, Canada, France) it is standard-of-care therapy where it has been shown to result in a median overall survival of 11.1 months. Related chemotherapies such as FOLFOX and FOLFIRI are used to treat colorectal cancer and other gastric cancers.

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit[3] and follow Amplia on Twitter[4] (@ampliatx) and LinkedIn[5].

[1] J Clin Oncol 41, 2023 (suppl 16; abstr e15128)



  1. ^ here (
  2. ^ NCT05355298 (
  3. ^ (
  4. ^ Twitter (
  5. ^ LinkedIn (

Read more

10 Terms to Include In Your Lease Or Rental Agreement

A rental or lease agreement outlays the rules agreed upon by landlords and tenants for their rental relationship. This agreement is a legally bind...

Business Training

Turn your property into a luxury Airbnb experience on a budget

Unlock the Secrets to Elevate Your Home's Earning Potential with Interior Design Expert Kellie Richardson Australians across the country are look...


What You Should Know About Display Homes

Do you intend to purchase or develop a home soon? If so, you're undoubtedly seeking for builders who can turn your thoughts or dreams into reality...


6 reasons why real estate is the safest long-term investment

An astonishing fact is that ninety percent of millionaires are getting rich by investing in Real Estate. Real estate provides the most reliable pl...


Perth Shines Brightly as Property Hotspot Amid Western Australia's Economic Boom

Perth's property market is riding an unprecedented wave, fueled by robust economic growth, surging population numbers, and an exceptionally tight re...


Why the Building Sector will be hit HARD in 2024

Since February, 2023, there has been an upswing in housing values even with rate rising measures by the Reserve Bank of Australia. The same growth i...